An Extended PD-L2 Cytoplasmic Domain Results From Alternative Splicing in NSCLC Cells.

Autor:	Dietz LL; Department of Biomedicine, Aarhus University, Denmark., Furman NT; Department of Biomedicine, Aarhus University, Denmark., Larsen TV; Department of Biomedicine, Aarhus University, Denmark., Daugaard TF; Department of Biomedicine, Aarhus University, Denmark., Thomsen EA; Department of Biomedicine, Aarhus University, Denmark., Keller JL; Department of Pathology., Aagaard L; Department of Biomedicine, Aarhus University, Denmark., Sorensen BS; Department of Clinical Biochemistry, Aarhus University Hospital, Denmark., Nielsen AL; Department of Biomedicine, Aarhus University, Denmark.
Jazyk:	angličtina
Zdroj:	Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2022 Nov-Dec 01; Vol. 45 (9), pp. 379-388. Date of Electronic Publication: 2022 Aug 30.
DOI:	10.1097/CJI.0000000000000439
Abstrakt:	Antibody-based immunotherapy targeting the interaction between programmed cell death 1 (PD-1) and its ligand PD-L1 has shown impressive clinical outcomes in various cancer types, including nonsmall cell lung cancer (NSCLC). However, regulatory mechanisms in this immune checkpoint pathway still needs clarification. PD-L2 is structurally homologous to PD-L1 and is a second PD-1 ligand. Alternative mRNA splicing from the CD274 and PDCD1LG2 genes holds the potential to generate PD-L1 and PD-L2 isoforms, respectively, with novel functionality in regulation of the PD-1 immune checkpoint pathway. Here, we describe alternative splicing in NSCLC cells potentially generating eight different PD-L2 isoforms from the PDCD1LG2 gene. Extension of exon 6 by four nucleotides is the most prominent alternative splicing event and results in PD-L2 isoform V with a cytoplasmic domain containing a 10 amino acid extension. On average 13% of the PDCD1LG2 transcripts in NSCLC cell lines and 22% of the transcripts in NSCLC tumor biopsies encode PD-L2 isoform V. PD-L2 isoform V localizes to the cell surface membrane but less efficiently than the canonical PD-L2 isoform I. The cytoplasmic domains of PD-1 ligands can affect immune checkpoint pathways by conferring membrane localization and protein stability and thereby represent alternative targets for immunotherapy. In addition, cytoplasmic domains are involved in intracellular signalling cascades in cancer cells. The presented observations of different cytoplasmic domains of PD-L2 will be important in the future delineation of the PD-1 immune checkpoint pathway. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu